School of Chemical Engineering, Sichuan University of Science & Engineering, Zigong, China.
State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, PR China.
J Biomol Struct Dyn. 2022 Feb;40(3):1172-1181. doi: 10.1080/07391102.2020.1823882. Epub 2020 Oct 5.
Wee1 kinase and Checkpoint kinase 1 (Chk1) kinase, which are well known to be involved in cancer, are promising targets for cancer therapy. Most of developed Wee1 inhibitors can inhibit activity of Chk1 kinase to different degrees as well. The poor selectivity brought side effects and selective inhibitor is needed. However, the selective mechanisms of Wee1 versus Chk1 are not clear. Therefore, the design of selective Wee1 and Chk1 inhibitors would provide a meaningful starting for the development of anticancer drugs with optimal efficacy. In this study, Wee1 inhibitors with different selectivity over Chk1 were chosen to analyze the selectivity mechanism by means of molecular docking, molecular dynamics simulations and binding free energy calculations. Two key residues of Wee1 kinase and two critical residues of Chk1 were mutated to detect their effect on ligand binding into protein. The results indicated that these residues play a pivotal role in the binding interactions of ligands to receptors through hydrogen bond and hydrophobic interaction with inhibitors. This may provide a better understanding of the selective mechanism of Wee1 and Chk1. It would be beneficial to the discovery and optimization of selective Wee1 and Chk1 inhibitors.Communicated by Ramaswamy H. Sarma.
Wee1 激酶和细胞周期检查点激酶 1(Chk1)激酶,它们众所周知与癌症有关,是癌症治疗的有前途的靶点。大多数已开发的 Wee1 抑制剂也能在不同程度上抑制 Chk1 激酶的活性。较差的选择性带来了副作用,需要选择性抑制剂。然而,Wee1 与 Chk1 之间的选择性机制尚不清楚。因此,设计选择性的 Wee1 和 Chk1 抑制剂将为开发具有最佳疗效的抗癌药物提供有意义的起点。在这项研究中,选择了对 Chk1 具有不同选择性的 Wee1 抑制剂,通过分子对接、分子动力学模拟和结合自由能计算来分析选择性机制。突变了 Wee1 激酶的两个关键残基和 Chk1 的两个关键残基,以检测它们对配体与蛋白质结合的影响。结果表明,这些残基通过氢键和疏水相互作用与抑制剂与配体结合到受体中发挥关键作用。这可能有助于更好地理解 Wee1 和 Chk1 的选择性机制。这将有助于发现和优化选择性 Wee1 和 Chk1 抑制剂。由 Ramaswamy H. Sarma 交流。